Also known as: CAR
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.
Researchers develop multiple strategies to enhance CAR T-cell therapy, including dual PGE2 receptor knockout for solid tumors and small-molecule switches using venetoclax and caffeine to control cellular activity and improve safety.
Pluri Inc. receives patent grant from China National Intellectual Property Administration for its proprietary 3D immune cell expansion and activation technology, expanding global IP protection across U.S., China, Japan, Korea, Australia and Israel.
